Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Qiagen CEO quits amid genetic sequencing U-turn, shares tumble

Stock Markets Oct 08, 2019 06:31AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
QIA
+1.02%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ILMN
+1.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

FRANKFURT (Reuters) - Qiagen's (DE:QIA) longtime CEO Peer Schatz resigned after the German genetic testing company disclosed a reversal of its genome sequencing strategy and a slump in its Chinese business, sending its shares tumbling 20%.

In a surprise announcement late on Tuesday, the maker of diagnostic kits for cancer and tuberculosis said it would stop developing its next-generation genome sequencing machines and instead collaborate with industry leader Illumina (O:ILMN).

For the third quarter, Qiagen cut its forecast for sales growth, adjusted for currency swings, to about 3%, down from a previous outlook of 4%-5%, with its China business turning out significantly weaker than expected.

It expected to report adjusted third-quarter earning-per-share of $0.35-0.36, in line with its previous forecast.

Qiagen plans to take a pre-tax restructuring charge of about $260-$265 million, mainly to write down assets linked to the development of next-generation sequencing (NGS) instruments.

It also cited an overhaul of its global manufacturing network and possible job cuts for the writedown.

The company said Thierry Bernard, the head of the group's molecular diagnostics business, would now take over as interim boss until a permanent CEO was found.

Shares plunged 20% to 23.47 euros at 0848 GMT, with the group losing close to 1.4 billion euros ($1.54 billion) in market value, after already shedding about 17% over the previous three months.

"The fall from grace of Qiagen shares since June suggests that the market was already positioning for an unfavorable Q3, but the CEO's departure will come as a surprise," said Berenberg analyst Scott Bardo, adding the business nevertheless held the promise of attractive underlying growth.

Qiagen's core work includes making diagnostics kits that test for a single genetic mutation to help decide on treatment. But in recent years the company has developed into a smaller NGS player, where a wider range or all genes are sequenced.

As part of a 15-year collaboration deal with NGS pioneer Illumina (O:ILMN), Qiagen will rely on its genetic diagnostic products running on its new partner's hardware.

Schatz, who will become a special adviser to the supervisory board, had been with the company for 27 years. Since he started as finance chief in 1993, Qiagen has grown from $2 million in annual revenues to $1.5 billion in 2018.

Qiagen CEO quits amid genetic sequencing U-turn, shares tumble
 

Related Articles

BlackBerry beats quarterly revenue estimates
BlackBerry beats quarterly revenue estimates By Reuters - Sep 27, 2022

(Reuters) -Canada's BlackBerry (NYSE:BB) Ltd beat analysts' estimates for second-quarter revenue on Tuesday, powered by demand for its QNX automotive software from automakers...

Today's Upgrades of Note
Today's Upgrades of Note By Investing.com - Sep 27, 2022

By Davit Kirakosyan Hyatt Hotels (NYSE:H) shares gained more than 3% Tuesday after Evercore ISI upgraded the company to Outperform from In Line with a price target of $100....

Canopy Growth to divest Canadian retail operations
Canopy Growth to divest Canadian retail operations By Reuters - Sep 27, 2022 1

(Reuters) -Canopy Growth Corp said on Tuesday it will divest its retail business across Canada, as the pot producer steps up efforts to turn profitable. The business includes...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email